Fortschr Neurol Psychiatr 2021; 89(05): 243-253
DOI: 10.1055/a-1472-5860
Übersicht

Symptomatische Behandlungsoptionen chronischer, neurologischer Gangstörungen

Options for the symptomatic treatment of chronic neurological gait disorders
Roman Schniepp
1   Deutsches Schwindel- und Gleichgewichtszentrum, Ludwig-Maximilians Universität München
2   Neurologische Klinik, Ludwig-Maximilians Universität München
,
Ken Möhwald
1   Deutsches Schwindel- und Gleichgewichtszentrum, Ludwig-Maximilians Universität München
2   Neurologische Klinik, Ludwig-Maximilians Universität München
,
Max Wuehr
1   Deutsches Schwindel- und Gleichgewichtszentrum, Ludwig-Maximilians Universität München
› Author Affiliations

Zusammenfassung

Störungen des Gehens, der Mobilität und Stürze sind häufige Gesundheitsprobleme von Patienten mit chronischen, neurologischen Erkrankungen. Daher ist es wichtig, neben der Behandlung der neurologischen Grunderkrankung auch symptomatische Therapieoptionen mit dem Ziel der Verbesserung des Gehens einzusetzen.

Mittels einer selektiven Literaturrecherche von Studien mit expliziter Untersuchung der Gehfähigkeit wurden symptomatische Therapiemöglichkeiten in den folgenden klinischen Entscheidungsfeldern identifiziert und diskutiert: (1) hypokinetische Gangstörung (z.B. bei M. Parkinson, Normaldruckhydrocephalus und vaskulärer Enzephalopathie), (2) Gangunsicherheit mit Ataxie (sensorisch und zerebellär) und (3) spastisch-paretische Gangstörung (bei Multipler Sklerose). Es werden medikamentöse und nicht-medikamentöse Therapieoptionen analysiert, speziell zu den Funktionsbereichen „Lokomotion“, „posturale Kontrolle“, „Modulation“ und „Adaptionsfähigkeit“. Die medikamentösen Behandlungskonzepte orientieren sich vorwiegend an den pathophysiologischen Veränderungen der Grunderkrankungen. Physikalisch-medizinische Basistherapien sowie Gang- und Bewegungstherapien erweitern das therapeutische Spektrum. Zudem können geh-relevante Einzelsymptome effizient mittels physikalisch-medizinischer oder pharmakologischer Therapien verbessert werden.

Die Behandlungsoptionen neurologischer Gangstörungen sind gut und systematisch untersucht und ermöglichen eine individuelle Anpassung an die zugrundeliegende neurologische Erkrankung, an die Funktionsdefizite der individuellen Gangstörung sowie an relevante Einzelsymptome, welche das Gehen nochmals verschlechtern.

Abstract

Gait and mobility impairments are common and relevant in patients with chronic neurological disorders. It reduces the health-related quality of life and induces falls with morbidity. Symptomatic treatment options are therefore necessary in order to improve the health status of patients with neurological disorders.

By means of a selective literature research focusing on studies with specific gait-related outcome measures. We discuss the differential treatment options for (1) hypokinetic gait disorders (Parkinson´s disease, Normal pressure hydrocephalus, vascular encephalopathy), (2) gait unsteadiness with ataxia (sensory and cerebellar ataxia), and (3) gait with spasticity and paresis (due to multiple sclerosis). Therapeutical options for the symptomatic treatment of gait disorders comprise non-pharmacological and pharmacological approaches. Both address the functional domains of “locomotion”, “postural control”, “modulation” and “adaptability” of gait.

Pharmacological options are orientated to pathophysiology of the underlying diseases. Supportive physiotherapeutic interventions offer broader and unspecific options for treatment. Clinical conditions that specifically disturb the execution of locomotion or gait can also be addressed by the provision of physical therapy or supportive devices.

Effective options for the symptomatic treatment of patients with neurological gait disorders are available. Applications of options addressing the pathophysiology of the underlying disease, a functional domain-based exercise and physiotherapy program, and the provision of walking aides for specific symptoms that further worsen gait performance can be recommended.



Publication History

Received: 02 December 2020

Accepted: 23 March 2021

Article published online:
23 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Stolze H, Klebe S, Baecker C. et al. Prevalence of gait disorders in hospitalized neurological patients. Mov Disord: Off J Mov Disord Soc 2005; 20: 89-94. DOI: 10.1002/mds.20266.
  • 2 Schlick C, Schniepp R, Loidl V. et al. Falls and fear of falling in vertigo and balance disorders: a controlled cross-sectional study. J Vestib Res 2016; 25: 241-251. DOI: 10.3233/VES-150564.
  • 3 Okuma Y. Freezing of gait and falls in Parkinson’s disease. J Parkinson’s Dis 2014; 4: 255-260
  • 4 Scf VDW, Hommel A, Bloem BR. et al. Promising non-pharmacological therapies in PD: targeting late stage disease and the role of computer based cognitive training. Parkinsonism Relat Disord 2018; 46 (Suppl 1): S42-S46. DOI: 10.1016/j.parkreldis.2017.09.002.
  • 5 Nieuwboer A. Cueing for freezing of gait in patients with Parkinson’s disease: a rehabilitation perspective. Mov Disord 2008; 23 (Suppl 2): S475-481. DOI: 10.1002/mds.21978.
  • 6 Roper JA, Kang N, Ben J. et al. Deep brain stimulation improves gait velocity in Parkinson’s disease: a systematic review and meta-analysis. J Neurol 2016; 263: 1195-1203. DOI: 10.1007/s00415-016-8129-9.
  • 7 Stolze H, Kuhtz-Buschbeck JP, Drucke H. et al. Gait analysis in idiopathic normal pressure hydrocephalus–which parameters respond to the CSF tap test?. Clin Neurophysiol 2000; 111: 1678-1686.
  • 8 Czerwosz L, Szczepek E, Blaszczyk JW. et al. Analysis of postural sway in patients with normal pressure hydrocephalus: effects of shunt implantation. Eur J Med Res 2009; 14 (Suppl 4): 53-58. DOI: 10.1186/2047-783x-14-s4-53.
  • 9 Schniepp R, Trabold R, Romagna A. et al. Walking assessment after lumbar puncture in normal-pressure hydrocephalus: a delayed improvement over 3 days. J Neurosurg 2017; 126: 148-157. DOI: 10.3171/2015.12.JNS151663.
  • 10 Smulders K, Dale ML, Carlson-Kuhta P. et al. Pharmacological treatment in Parkinson’s disease: effects on gait. Parkinsonism Relat Disord 2016; 31: 3-13. DOI: 10.1016/j.parkreldis.2016.07.006.
  • 11 Group PS. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004; 351: 2498-2508
  • 12 Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord 2007; 22: 2141-2148. quiz 2295. DOI: 10.1002/mds.21578.
  • 13 Pozzi NG, Brumberg J, Todisco M. et al. Striatal dopamine deficit and motor impairment in idiopathic normal pressure hydrocephalus. Mov Disord 2020 DOI: 10.1002/mds.28366
  • 14 Hauser RA, Heritier S, Rowse GJ. et al. Droxidopa and reduced falls in a trial of Parkinson disease patients with neurogenic orthostatic hypotension. Clin Neuropharmacol 2016; 39: 220-226. DOI: 10.1097/WNF.0000000000000168.
  • 15 Ilg W, Synofzik M, Brötz D. et al. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 2009; 73: 1823-1830
  • 16 Keller JL, Bastian AJ. A home balance exercise program improves walking in people with cerebellar ataxia. Neurorehabil Neural Repair 2014; 28: 770-778
  • 17 Ilg W, Schatton C, Schicks J. et al. Video game–based coordinative training improves ataxia in children with degenerative ataxia. Neurology 2012; 79: 2056-2060
  • 18 Missaoui B, Thoumie P. How far do patients with sensory ataxia benefit from so-called “proprioceptive rehabilitation”?. Neurophysiologie Clin/Clin Neurophysiol 2009; 39: 229-233
  • 19 Missaoui B, Thoumie P. Balance training in ataxic neuropathies. Effects Balance Gait Parameters. Gait Posture 2013; 38: 471-476. DOI: 10.1016/j.gaitpost.2013.01.017.
  • 20 Taveggia G, Villafañe JH, Vavassori F. et al. Multimodal treatment of distal sensorimotor polyneuropathy in diabetic patients: a randomized clinical trial. J Manipulative Physiol Ther 2014; 37: 242-252
  • 21 Horak FB, Jones-Rycewicz C, Black FO. et al. Effects of vestibular rehabilitation on dizziness and imbalance. Otolaryngol-Head Neck Surg: Off J Am Acad Otolaryngol Head Neck Surg 1992; 106: 175-180
  • 22 Krebs DE, Gill-Body KM, Riley PO. et al. Double-blind, placebo-controlled trial of rehabilitation for bilateral vestibular hypofunction: preliminary report. Otolaryngol Head Neck Surg 1993; 109: 735-741. DOI: 10.1177/019459989310900417.
  • 23 Wuehr M, Decker J, Schniepp R. Noisy galvanic vestibular stimulation: an emerging treatment option for bilateral vestibulopathy. J Neurol 2017; 264: 81-86
  • 24 Krebs DE, Gill-Body KM, Riley PO. et al. Double-blind, placebo-controlled trial of rehabilitation for bilateral vestibular hypofunction: preliminary report. Otolaryngol Head Neck Surg 1993; 109: 735-741
  • 25 McGibbon CA, Krebs DE, Parker SW. et al. Tai Chi and vestibular rehabilitation improve vestibulopathic gait via different neuromuscular mechanisms: preliminary report. BMC Neurol 2005; 5: 1-12
  • 26 Quigley PA, Bulat T, Schulz B. et al. Exercise interventions, gait, and balance in older subjects with distal symmetric polyneuropathy: a three-group randomized clinical trial. Am J Phys Med Rehabil 2014; 93: 1-12. quiz 13–16. DOI: 10.1097/phm.0000000000000052.
  • 27 Feil K, Bremova T, Muth C. et al. Update on the pharmacotherapy of cerebellar ataxia and nystagmus. Cerebellum (London, England) 2016; 15: 38-42. DOI: 10.1007/s12311-015-0733-1.
  • 28 Schniepp R, Strupp M, Wuehr M. et al. Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series. Cerebellum Ataxias 2016; 3: 8. DOI: 10.1186/s40673-016-0046-2.
  • 29 Schniepp R, Wuehr M, Neuhaeusser M. et al. 4-aminopyridine and cerebellar gait: a retrospective case series. J Neurol 2012; 259: 2491-2493. DOI: 10.1007/s00415-012-6595-2.
  • 30 Van De Warrenburg B, Van Gaalen J, Boesch S. et al. EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol 2014; 21: 552-562
  • 31 Cameron MH, Wagner JM. Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment. Curr Neurol Neurosci Rep 2011; 11: 507-515. DOI: 10.1007/s11910-011-0214-y.
  • 32 Nerz C, Schwickert L, Becker C. et al. Effectiveness of robot-assisted training added to conventional rehabilitation in patients with humeral fracture early after surgical treatment: protocol of a randomised, controlled, multicentre trial. Trials 2017; 18: 589. DOI: 10.1186/s13063-017-2274-z.
  • 33 Orsnes GB, Sørensen PS, Larsen TK. et al. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 2000; 101: 244-248. DOI: 10.1034/j.1600-0404.2000.101004244x./.
  • 34 Coghe G, Pau M, Corona F. et al. Walking improvements with nabiximols in patients with multiple sclerosis. J Neurol 2015; 262: 2472-2477
  • 35 De Blasiis P, Siani MF, Fullin A. et al. Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity. Mult Scler Relat Disord. 2021 [in press]. https://doi.org/10.1016/j.msard.2021.102805